Yahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang, & Hongqi Tian. (2023). Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Frontiers Media S.A..
Chicago Style (17th ed.) CitationYahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang, and Hongqi Tian. Preclinical Characterization of Tunlametinib, a Novel, Potent, and Selective MEK Inhibitor. Frontiers Media S.A., 2023.
MLA (9th ed.) CitationYahong Liu, et al. Preclinical Characterization of Tunlametinib, a Novel, Potent, and Selective MEK Inhibitor. Frontiers Media S.A., 2023.
Warning: These citations may not always be 100% accurate.